Vandortuzumab vedotin: Difference between revisions

From WikiMD's Wellness Encyclopedia

Newer edit →
No edit summary
 
CSV import
Line 1: Line 1:
== Vandortuzumab Vedotin (RG7450): A Potential Therapeutic Agent for Cancer ==
== Vandortuzumab vedotin ==


'''Vandortuzumab Vedotin (RG7450)''' is a humanized [[monoclonal antibody]] that was specifically engineered with the intention of treating various forms of cancer. Created through biotechnological advancements, its development underscores the growing interest and investment in targeted therapies within the oncology field.
'''Vandortuzumab vedotin''' is an investigational [[antibody-drug conjugate]] (ADC) designed for the treatment of [[cancer]]. It is composed of a monoclonal antibody targeting the protein [[CD70]], which is linked to the cytotoxic agent [[monomethyl auristatin E]] (MMAE) via a protease-cleavable linker. This ADC is being developed to deliver the cytotoxic drug directly to cancer cells expressing CD70, thereby minimizing systemic exposure and reducing side effects.
 
=== Background ===
 
* '''Classification''': Humanized monoclonal antibody.
* '''Primary Objective''': Treatment of cancer.


=== Mechanism of Action ===
=== Mechanism of Action ===
Vandortuzumab vedotin works by specifically binding to CD70, a protein that is overexpressed in various types of cancer cells, including [[renal cell carcinoma]], [[non-Hodgkin lymphoma]], and [[glioblastoma]]. Upon binding to CD70, the ADC is internalized into the cancer cell, where the linker is cleaved by lysosomal enzymes, releasing MMAE. MMAE then disrupts the microtubule network within the cell, leading to cell cycle arrest and apoptosis.


Vandortuzumab Vedotin, like other antibody-drug conjugates, is designed to selectively target cancer cells. It combines the specific targeting capabilities of monoclonal antibodies with the cytotoxic potency of small-molecule drugs. By honing in on cancer cells and delivering a potent drug payload, the compound seeks to eliminate tumor cells while sparing healthy tissue, thereby reducing systemic side effects<ref>Jones RL, et al. Antibody-drug conjugates in solid tumors: a look into novel targets. Journal of Hematology & Oncology. 2021;14(1):1-14.</ref>.
=== Development and Clinical Trials ===
Vandortuzumab vedotin is being developed by [[Seattle Genetics]], a biotechnology company known for its work in ADCs. The drug has undergone several phases of clinical trials to evaluate its safety, tolerability, and efficacy in patients with CD70-positive cancers. Early-phase trials have shown promising results, with manageable side effects and evidence of anti-tumor activity.


=== Developer Information ===
=== Side Effects ===
As with other ADCs, the side effects of vandortuzumab vedotin are primarily related to the cytotoxic payload. Common adverse effects include [[neutropenia]], [[peripheral neuropathy]], and fatigue. The safety profile is continuously monitored in clinical trials to ensure that the benefits outweigh the risks.


* '''Company''': Vandortuzumab Vedotin was developed through a collaboration between [[Genentech]] and [[Roche]], two leaders in the biopharmaceutical industry.
=== Future Directions ===
Research is ongoing to explore the full potential of vandortuzumab vedotin in various cancer types. Combination therapies with other anticancer agents are also being investigated to enhance its efficacy. The development of biomarkers to predict response to treatment is another area of active research.


=== Clinical Development and Outcome ===
== Related Pages ==
* [[Antibody-drug conjugate]]
* [[Monomethyl auristatin E]]
* [[CD70]]
* [[Seattle Genetics]]


* '''Research Phase''': Vandortuzumab Vedotin underwent various stages of clinical trials to assess its safety, efficacy, and potential therapeutic applications in oncology.
== References ==
* '''Discontinuation''': In 2017, the development of Vandortuzumab Vedotin was halted. The exact reasons for discontinuation often encompass a range of factors, from observed side effects to economic considerations or strategic focuses of the developing company<ref>Thomson Reuters. Discontinuation of clinical trials – reasons, challenges, and guidance. PLoS ONE. 2018;13(8):e020 in006.</ref>.
{{Reflist}}


=== Implications ===
[[File:Vedotin_ADCs.svg|thumb|right|Diagram of vedotin-based ADCs, showing the structure of the linker and payload.]]


The development and subsequent discontinuation of Vandortuzumab Vedotin emphasizes the complexities and challenges inherent in drug development. While many compounds enter clinical trials, a significantly smaller number achieve market approval. However, each attempt contributes to the broader understanding of disease mechanisms and therapeutic interventions, potentially paving the way for future innovations<ref>Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3(8):711-715.</ref>.
[[Category:Experimental cancer drugs]]
 
[[Category:Antibody-drug conjugates]]
== Conclusion ==
 
Vandortuzumab Vedotin stands as a testament to the continuous efforts within the pharmaceutical industry to innovate and improve therapeutic options for patients with cancer. Although this specific compound did not progress to market, the knowledge gained from its development remains invaluable for future research endeavors.
 
== References ==
<references />
{{monoclonals for tumors}}
{{monoclonal-antibody-stub}}
[[Category:Monoclonal antibodies]]
[[Category:Abandoned drugs]]
{{nt}}

Revision as of 15:46, 9 February 2025

Vandortuzumab vedotin

Vandortuzumab vedotin is an investigational antibody-drug conjugate (ADC) designed for the treatment of cancer. It is composed of a monoclonal antibody targeting the protein CD70, which is linked to the cytotoxic agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. This ADC is being developed to deliver the cytotoxic drug directly to cancer cells expressing CD70, thereby minimizing systemic exposure and reducing side effects.

Mechanism of Action

Vandortuzumab vedotin works by specifically binding to CD70, a protein that is overexpressed in various types of cancer cells, including renal cell carcinoma, non-Hodgkin lymphoma, and glioblastoma. Upon binding to CD70, the ADC is internalized into the cancer cell, where the linker is cleaved by lysosomal enzymes, releasing MMAE. MMAE then disrupts the microtubule network within the cell, leading to cell cycle arrest and apoptosis.

Development and Clinical Trials

Vandortuzumab vedotin is being developed by Seattle Genetics, a biotechnology company known for its work in ADCs. The drug has undergone several phases of clinical trials to evaluate its safety, tolerability, and efficacy in patients with CD70-positive cancers. Early-phase trials have shown promising results, with manageable side effects and evidence of anti-tumor activity.

Side Effects

As with other ADCs, the side effects of vandortuzumab vedotin are primarily related to the cytotoxic payload. Common adverse effects include neutropenia, peripheral neuropathy, and fatigue. The safety profile is continuously monitored in clinical trials to ensure that the benefits outweigh the risks.

Future Directions

Research is ongoing to explore the full potential of vandortuzumab vedotin in various cancer types. Combination therapies with other anticancer agents are also being investigated to enhance its efficacy. The development of biomarkers to predict response to treatment is another area of active research.

Related Pages

References

<references group="" responsive="1"></references>


Diagram of vedotin-based ADCs, showing the structure of the linker and payload.
Retrieved from "https://wikimd.com/index.php?title=Vandortuzumab_vedotin&oldid=6200134"